Galcanezumab

Status:

Red

Decision Date:

December 2020

Comments

RED¹: NICE TA659 - prevention of migraine in adults who have ≥ 4 migraine days per month. See local commissioning algorithm for further details.

CCG commissioned  

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again